Ziprasidone
Brand names: Geodon, Zeldox
Ziprasidone is a second-generation (atypical) antipsychotic used in the management of schizophrenia and bipolar disorder.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It antagonises dopamine D2 and serotonin 5-HT2A receptors, with additional activity at other serotonergic and adrenergic receptors contributing to its effect.
Prescribing in practice
- It can prolong the QT interval, so it is contraindicated in those with known QT prolongation, recent myocardial infarction or uncompensated heart failure, and caution is needed with other QT-prolonging drugs.
- Oral absorption is substantially enhanced when taken with food, so consistency in administration is important.
- Use with caution in those with risk factors for electrolyte disturbance, which can potentiate arrhythmia risk.
Monitoring
Monitor ECG where there are cardiac risk factors, along with electrolytes, weight and metabolic parameters.
Counselling the patient
- Take the medicine with food to ensure it is absorbed properly.
- Report palpitations, fainting or dizziness without delay.
- Do not stop treatment suddenly without discussing it with your prescriber.
Evidence & guidelines
Atypical antipsychotics are established options for schizophrenia, with choice guided by side-effect profile per NICE guidance.
Reference: Lieberman et al. NEJM 2005 (CATIE trial); BAP Guidelines for Schizophrenia; MHRA SPC Zeldox/Geodon; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- ASA Physical Status Classification · Pre-operative Risk
- NUTRIC Score for ICU Nutrition Risk · Nutrition
- POSSUM Score for Surgical Morbidity and Mortality · Perioperative Risk
- SORT (Surgical Outcome Risk Tool) · Perioperative Risk
- Revised Cardiac Risk Index (RCRI / Lee Index) · Perioperative Risk
- ASA Physical Status Classification · Perioperative Risk
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185